Rapamycin (RAPA) is an immunosuppressive drug that prevents and treats graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplant (HCT). One possible mechanism for its efficacy is induction of tolerance, through increased number or enhanced survival of regulatory T cells. In our experiments, B10.D2 BM and splenocytes were injected into lethally irradiated BALB/cJ recipients. The mice received i.p. injections of either RAPA or vehicle control on days 1-28. There was a significant survival advantage in RAPA-treated mice. Evaluation of the skin biopsies showed a dense cellular infiltrate in RAPA-treated mice. Further characterization of these cells revealed a higher percentage of regulatory T cells characterized by FoxP3-positive cells in high-dose RAPA-treated mice as compared with controls on day 30. This effect appears to be dose dependent. When peripheral blood analysis for FoxP3-positive cells was performed, there was no significant difference observed in the RAPA-treated mice as compared with control mice. These data show a novel mechanism of rapamycin in GVHD, accumulation of regulatory T cells in the GVHD target tissue: the skin. © 2010 Macmillan Publishers Limited All rights reserved.
CITATION STYLE
Palmer, J. M., Chen, B. J., Deoliveira, D., Le, N. D., & Chao, N. J. (2010). Novel mechanism of rapamycin in GVHD: Increase in interstitial regulatory T cells. Bone Marrow Transplantation, 45(2), 379–384. https://doi.org/10.1038/bmt.2009.140
Mendeley helps you to discover research relevant for your work.